Overview

ATN-161 in Advanced Renal Cell Cancer

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Attenuon